Ketchum secures Tygacil UK push

Ketchum is to promote Wyeth’s pre-launch injectable antibiotic product Tygacil in the UK.

The agency won a three-way pitch to secure the account (PRWeek, 8 October) – and will also promote Wyeth’s long-established injectable penicillin Tazocin.

Tygacil may represent a major advance in the treatment of serious hospital-based infections including ‘superbug’ MRSA.

The product, one of a crop of drugs unveiled to investment analysts in the US earlier this year, is currently in phase III clinical trials.

Ketchum scooped a PR contract to promote Tygacil globally in a pitch process held at Wyeth’s global HQ in Pennsylvania four months ago (PRWeek, 25 June).

The campaign for Tygacil will involve the promotion of yet-to-be-published data on the product’s efficacy.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Recommended for you

Recommended for you

Explore further